Idorsia Pharmaceuticals Japan Ltd

**Sosei Heptares Acquires Idorsia Pharmaceuticals Business in Japan and APAC Excluding China** **October 3, 2022** - Allschwil, Switzerland and Tokyo, Japan - Idorsia Pharmaceuticals Ltd. (SIX: IDIA) and Sosei Group Corporation (TSE: 4565) today announced that Sosei Heptares has acquired Idorsia's pharmaceutical business in Japan and the Asia-Pacific region (APAC) excluding China. Idorsia is a high-potential biopharmaceutical company headquartered in Allschwil, Switzerland, a prominent biotech hub in Europe. This acquisition reinforces Sosei Heptares' position as a leading biopharmaceutical company in Japan and APAC. The acquisition includes Idorsia's commercial operations, development pipeline, and employees in the acquired territories. Sosei Heptares will leverage its existing infrastructure and expertise to accelerate the development and commercialization of Idorsia's innovative therapies in the region. "We are delighted to welcome Idorsia's business in Japan and APAC to the Sosei Heptares family," commented Shinichi Tamura, Chairman, President, and CEO of Sosei Heptares. "This acquisition strengthens our presence in these important markets and provides us with a broader portfolio of innovative medicines to address unmet medical needs." "This transaction is a testament to the value of our pharmaceutical business and its potential in Japan and APAC," said Jean-Paul Clozel, MD, Chief Executive Officer of Idorsia. "We believe that Sosei Heptares is well-positioned to continue developing and commercializing our therapies in these regions." The financial terms of the acquisition were not disclosed.